Waverley Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Larry Thiessen

İcra Kurulu Başkanı

CA$45.0k

Toplam tazminat

CEO maaş yüzdesi	100.0%
CEO görev süresi	4.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	4.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Larry Thiessen'un ücretlendirmesi Waverley Pharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-CA$2m
Mar 31 2024	n/a	n/a	-CA$2m
Dec 31 2023	CA$45k	CA$45k	-CA$2m
Sep 30 2023	n/a	n/a	-CA$1m
Jun 30 2023	n/a	n/a	-CA$910k
Mar 31 2023	n/a	n/a	-CA$693k
Dec 31 2022	CA$45k	CA$45k	-CA$664k
Sep 30 2022	n/a	n/a	-CA$725k
Jun 30 2022	n/a	n/a	-CA$810k
Mar 31 2022	n/a	n/a	-CA$934k
Dec 31 2021	CA$45k	CA$45k	-CA$797k
Sep 30 2021	n/a	n/a	-CA$851k
Jun 30 2021	n/a	n/a	-CA$642k
Mar 31 2021	n/a	n/a	-CA$697k
Dec 31 2020	CA$33k	CA$33k	-CA$706k

Tazminat ve Piyasa: Larry 'nin toplam tazminatı ($USD 32.19K ), Canadian pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 169.13K ).

Tazminat ve Kazançlar: Larry 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Larry Thiessen

4.8yrs

Görev süresi

CA$45,000

Tazminat

Mr. Larry Thiessen MBA, serves as President and Chief Executive Officer at Waverley Pharma Inc. since February 1, 2020 and also serves as its Director since November 22, 2023. He has extensive pharmaceutic...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Larry Thiessen	President	less than a year	CA$45.00k	Veri yok
Albert Friesen	Chairman of the Board	7.9yrs	Veri yok	74.61% CA$ 604.4k
P. Enns	Independent Director	7.9yrs	Veri yok	0.19% CA$ 1.5k
James Kinley	Director	less than a year	Veri yok	0.10% CA$ 847.5

4.5yrs

Ortalama Görev Süresi

52yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: WAVE 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.5 yıldır).

Waverley Pharma Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Waverley Pharma Inc. Elects James Kinley as Director

Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Waverley Pharma Inc. Announces Changes to Board of Directors

Recent updates

Waverley Pharma Inc. (TSXV:WAVE) entered into a definitive agreement to acquire C & R Pharmacy, LLC for $0.51 million.

First half 2024 earnings released: CA$0.011 loss per share (vs CA$0.011 loss in 1H 2023)

Waverley Pharma Inc. Elects James Kinley as Director

First quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.006 loss in 1Q 2023)

Full year 2023 earnings released: CA$0.041 loss per share (vs CA$0.012 loss in FY 2022)

Waverley Pharma Inc., Annual General Meeting, Jun 20, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Waverley Pharma Inc. Announces Changes to Board of Directors

Waverley Pharma Inc. Announces Changes to Board of Directors

Insufficient new directors

Insufficient new directors

Second quarter 2023 earnings released: CA$0.004 loss per share (vs CA$0 in 2Q 2022)

Insufficient new directors

Waverley Pharma Inc., Annual General Meeting, Jun 21, 2023

First quarter 2023 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 1Q 2022)

Insufficient new directors

Full year 2022 earnings released: CA$0.012 loss per share (vs CA$0.015 loss in FY 2021)

Insufficient new directors

Waverley Pharma Inc. Provides Update on its PARP-1 Inhibitor Program

Third quarter 2022 earnings released: CA$0.002 loss per share (vs CA$0.004 loss in 3Q 2021)

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: EPS: CA$0 (vs CA$0.003 loss in 2Q 2021)

Insufficient new directors

Insufficient new directors

First quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.003 loss in 1Q 2021)

Full year 2021 earnings released: CA$0.015 loss per share (vs CA$0.013 loss in FY 2020)

Insufficient new directors

Waverley Pharma Inc., Annual General Meeting, Jun 15, 2022

Second quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.004 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.003 loss per share (vs CA$0.003 loss in 1Q 2020)

Full year 2020 earnings released: CA$0.013 loss per share (vs CA$0.022 loss in FY 2019)

Waverley Pharma Announces Tentative ANDA Approval for Pemetrexed in the United States

First half earnings released

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş